Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine.
about
Neonatal abstinence syndrome: treatment and pediatric outcomesStress, dysregulation of drug reward pathways, and the transition to drug dependenceBehavioral and neurochemical effects of amphetamine analogs that release monoamines in the squirrel monkeyκ-opioid receptor/dynorphin system: genetic and pharmacotherapeutic implications for addictionInteraction between dysfunctional connectivity at rest and heroin cues-induced brain responses in male abstinent heroin-dependent individualsAffective and neuroendocrine effects of withdrawal from chronic, long-acting opiate administration.Increased dopamine receptor activity in the nucleus accumbens shell ameliorates anxiety during drug withdrawal.Decreased reinforcing effects of cocaine following 2 weeks of continuous D-amphetamine treatment in rats.Drug-induced and genetic alterations in stress-responsive systems: Implications for specific addictive diseases.Predictors of buprenorphine-naloxone dosing in a 12-week treatment trial for opioid-dependent youth: secondary analyses from a NIDA Clinical Trials Network study.Opioid addiction and abuse in primary care practice: a comparison of methadone and buprenorphine as treatment options.Human behavioral pharmacology, past, present, and future: symposium presented at the 50th annual meeting of the Behavioral Pharmacology Society.Is slow-onset long-acting monoamine transport blockade to cocaine as methadone is to heroin? Implication for anti-addiction medications.Sustained release d-amphetamine reduces cocaine but not 'speedball'-seeking in buprenorphine-maintained volunteers: a test of dual-agonist pharmacotherapy for cocaine/heroin polydrug abusersActivation of µ-opioid receptors and block of Kir3 potassium channels and NMDA receptor conductance by L- and D-methadone in rat locus coeruleus.The neurobiology of opioid dependence: implications for treatment.Family support, quality of life and concurrent substance use among methadone maintenance therapy clients in ChinaEffects of chronic d-amphetamine administration on the reinforcing strength of cocaine in rhesus monkeysNerve growth factor β polypeptide (NGFB) genetic variability: association with the methadone dose required for effective maintenance treatmentMultiple OPR genes influence personality traits in substance dependent and healthy subjects in two American populationsPharmacologic treatments for opioid dependence: detoxification and maintenance options.A randomized trial of methadone initiation prior to release from incarcerationDistinct effects of individual opioids on the morphology of spines depend upon the internalization of mu opioid receptorsElevated Hair Cortisol Levels among Heroin Addicts on Current Methadone Maintenance Compared to ControlsOpiate users' perceived barriers against attending methadone maintenance therapy: a qualitative study in China.Making a bad thing worse: adverse effects of stress on drug addiction.Opiate addiction and cocaine addiction: underlying molecular neurobiology and genetics.Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes.Punishment induces risky decision-making in methadone-maintained opiate users but not in heroin users or healthy volunteersCan the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?Extreme marginalization: addiction and other mental health disorders, stigma, and imprisonmentCharacter pathology and neuropsychological test performance in remitted opiate dependenceCharacterization of methadone as a β-arrestin-biased μ-opioid receptor agonist.Methadone Reverses Analgesic Tolerance Induced by Morphine Pretreatment.Flexible dosing of tincture of opium in the management of opioid withdrawal: pharmacokinetics and pharmacodynamics.Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey.Association of genetic variation in pharmacodynamic factors with methadone dose required for effective treatment of opioid addiction.Disrupted coupling of large-scale networks is associated with relapse behaviour in heroin-dependent men.Disrupted coupling of large-scale networks is associated with relapse behaviour in heroin-dependent men.
P2860
Q24611058-AD1D1135-CAD1-4AEA-B2CC-EAA6D4A6E8AAQ24629577-F6BF1F27-19BD-4F43-955D-B01FA6E8B457Q24651855-AE45766B-9141-4C87-9BFD-27EC42821214Q26864309-C2E032DE-BD7E-400E-AA55-F5ACBC23143FQ28477519-58CEA77D-0F4C-4584-9E51-2138387CB387Q30426271-7F975DA9-352D-460A-B06B-B8833D069C66Q30448787-893F0894-5B31-4DFB-A587-F3BAC4806C3FQ30479418-DCBE6E8F-F92C-462A-9201-FA9DAD6891B7Q33643136-6F9D1A9F-FBA3-43F0-A46E-88D7894EFF7AQ33653252-FB9598A6-19DB-4651-8DA3-9B59D7614FC7Q33688813-E327C84D-B804-44FE-B178-26F60C054869Q34033200-C4EA50BE-B0AA-4E74-AF71-4A8E3C07BA8BQ34136977-FCE4ABA5-471C-459F-B885-8266EA0CAD7DQ34300251-5E07BD6B-6B5F-49FD-88AC-2852CA64EDCBQ34399326-3A9D82FF-915A-4B9E-8592-77C97A18C1CAQ34787830-04B6C1C5-0B81-445A-AAF5-7432EC41B1A9Q35038674-872F671A-2C73-4CBC-B79A-AF23FE31BAB2Q35065338-5659287B-991B-4F4F-81C7-D6A00B4F38C7Q35087543-B9EC3B99-D42D-4494-9EC8-3FC7CE34F20FQ35182420-8465DA3C-9888-47F7-88EE-F8C19A096EF2Q35454866-37B12E9F-3D3A-465F-A424-8F43C9CEFE12Q35752644-3DC48055-9DC3-4C2A-9ED1-E15DBBC89BA8Q35911045-7905865C-B90B-4013-89AD-781D0D47CF9CQ35969069-23A1412B-E0DC-4685-88E6-FB412407FE8FQ36083158-0C4EC6EF-CEF8-4370-9855-25CAC07C3FC8Q36407029-CBB19828-7C51-4FB0-ADF5-99D0BA436FD5Q36499673-FF039C95-B37C-41DA-B492-495D24FAE787Q36698474-13551F36-E452-47EF-A875-39B346A2DF5AQ36804132-C157FDAB-60C3-454A-917C-06B5E5FD3C8EQ36928874-CE034DD1-CEEC-4236-9DD4-A4F55365F774Q37027238-B8F811A5-7F7B-49BA-8589-1BC4B09AAA07Q37078370-516785D7-3E32-43BB-A765-EDBB4E0F60DAQ37115757-B68A760B-A52F-44B1-982A-EE8A959F18BAQ37137778-1A49CF6B-CC1A-41DB-8B21-430AE7BB4B8BQ37142434-D1EB9F62-3146-462D-9940-DBD0C4390DBBQ37346293-D025035F-9EF1-4D1E-9DA1-BFF4CA0E96F6Q37401604-2DE28A31-575E-4DA0-B6C9-242C2A7C2651Q47909598-2A24F63D-7C95-450A-96C3-1798744A473CQ48096282-15FF9275-A277-45EA-96EF-8689411C63BF
P2860
Methadone-related opioid agonist pharmacotherapy for heroin addiction. History, recent molecular and neurochemical research and future in mainstream medicine.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Methadone-related opioid agoni ...... future in mainstream medicine.
@ast
Methadone-related opioid agoni ...... future in mainstream medicine.
@en
type
label
Methadone-related opioid agoni ...... future in mainstream medicine.
@ast
Methadone-related opioid agoni ...... future in mainstream medicine.
@en
prefLabel
Methadone-related opioid agoni ...... future in mainstream medicine.
@ast
Methadone-related opioid agoni ...... future in mainstream medicine.
@en
P1476
Methadone-related opioid agoni ...... future in mainstream medicine.
@en
P2093
P304
P407
P577
2000-01-01T00:00:00Z